4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.
Tarsus Pharmaceuticals, Inc. (TARS) operates in the Biotechnology industry and is headquartered in Irvine, United States with about 370 employees. Its market capitalization is roughly $3 billion. In the fiscal year ended 2025-12-31, TARS reported $451M in revenue and ($66M) in net income.
Tarsus Pharmaceuticals, Inc., a commercial stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for eye care in the United States.
Interactive charts & full statements → Open the TARS valuation workbench →
| Income statement | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Total Revenue | $451M | $183M | $17M | $26M | — |
| Gross Profit | $421M | $170M | $16M | $25M | — |
| Operating Income (EBIT) | ($71M) | ($121M) | ($143M) | ($63M) | — |
| Net Income | ($66M) | ($116M) | ($136M) | ($62M) | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly income statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
|---|---|---|---|---|---|---|
| Total Revenue | $162M | $152M | $119M | $103M | $78M | — |
| Gross Profit | $153M | $141M | $110M | $96M | $73M | — |
| Operating Income (EBIT) | ($6M) | ($8M) | ($14M) | ($22M) | ($26M) | — |
| Net Income | ($7M) | ($8M) | ($13M) | ($20M) | ($25M) | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Balance sheet | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Total Assets | $562M | $377M | $266M | $228M | — |
| Total Liabilities | $219M | $152M | $68M | $35M | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive TARS viewer.
About TickerBase · Data methodology & sources